Corient Private Wealth
TLSI icon

Corient Private Wealth’s TriSalus Life Sciences TLSI Stock Holding History

Corient Private Wealth’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670K Buy
147,152
+56,152
+62% +$223K ﹤0.01% 2036
2026
Q1 		$364K Buy
+91,000
New +$446K ﹤0.01% 2215
2025
Q4 		– Sell
-75,700
Closed -$352K – 2793
2025
Q3 		$352K Buy
+75,700
New +$354K ﹤0.01% 2022

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Corient Private Wealth's TLSI Position: Q2 2026 in Review

Corient Private Wealth increased its TriSalus Life Sciences (TLSI) stake by 62% in Q2 2026, buying an estimated $223K and bringing the position to 147,152 shares worth $670K. The position accounts for ﹤0.01% of the portfolio, ranked #2036.

Corient Private Wealth first reported a position in TLSI in Q3 2025 and has held it in 3 quarters since. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Corient Private Wealth held 147,152 shares of TriSalus Life Sciences worth $670K as of Q2 2026.
  • Corient Private Wealth bought 56,152 TriSalus Life Sciences shares in Q2 2026, an estimated $223K.
  • TriSalus Life Sciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2036 holding.
  • Corient Private Wealth first reported a position in TriSalus Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • 78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.